Melfalán Aspen

Melphalan, the active ingredient in Melfalán Aspen, is an alkylating agent presented as a sterile injectable solution for intravenous use. It is employed in the treatment of multiple myeloma, ovarian cancer and malignant melanoma in adult patients.

GNH USA supplies Melfalán Aspen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melfalán Aspen is an alkylating chemotherapy used in hematologic and solid tumour protocols.

Multiple myeloma: provides cytoreduction and disease control in relapsed or refractory cases. Ovarian cancer: contributes to tumour shrinkage when combined with platinum‑based regimens. Malignant melanoma: used in high‑dose regimens for advanced disease.

Melfalán Aspen may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue and weakness - Alopecia (hair loss) - Myelosuppression (decreased blood cell counts) - Mucositis (mouth sores) - Diarrhea

Serious or Rare Side Effects: - Secondary malignancies (e.g., acute leukemia) - Severe neutropenia with infection risk - Hemorrhagic cystitis - Pulmonary toxicity (interstitial pneumonitis) - Renal impairment - Life‑threatening allergic reactions

Before initiating therapy, clinicians should assess baseline organ function and monitor patients closely.

Monitor blood counts: perform regular CBC to detect myelosuppression. Assess renal function: adjust dosing if creatinine clearance is reduced. Avoid concurrent nephrotoxic drugs: increased risk of renal toxicity. Pregnancy: use only if potential benefit justifies risk to the fetus. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with several agents, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: additive bone‑marrow toxicity. - Combination with high‑dose radiation therapy: heightened tissue damage. - Co‑administration with nephrotoxic antibiotics (e.g., aminoglycosides): increased renal risk.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampicin): may reduce melphalan exposure. - Use with granulocyte‑colony stimulating factor (G‑CSF): may mask neutropenia. - Concomitant anticoagulants: potential for increased bleeding.